The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

Hematologic Malignancies
09:31

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Hairy Cell Leukemia Highlights - Moxetumomab Pasudotox for Relapsed/Refractory Disease & Concurrent Rituximab with Cladribine for 1st Line

FEATURING Abdulraheem Yacoub
  • 60 views
  • August 2, 2019
07:15

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 CML Updates - Criteria for Treatment Discontinuation & Treatment-Free Remission After Nilotinib (ENESTop Study)

FEATURING Abdulraheem Yacoub
  • 163 views
  • August 2, 2019
  • 1
09:20

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 MDS & MPN Update - Luspatercept in Lower-Risk MDS & Ruxolitinib Study + PI3K in Myelofibrosis

FEATURING Abdulraheem Yacoub
  • 88 views
  • August 2, 2019
15:41

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Targeted Therapy Drugs for AML - CPX-351, FLT3, IDH Inhibitors, BCL-2, & Hedgehog Pathway Inhibitor

FEATURING Tara Lin
  • 253 views
  • August 19, 2019
  • 1
12:21

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Update on Recent Developments in AML - CX-01, HuF59 Anti-CD47 Antibody, Ivosidenib + Azacitidine

FEATURING Tara Lin
  • 193 views
  • August 19, 2019
10:39

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Myeloma Update: Lenalidomide vs Observation in Patients with High-Risk Smoldering Multiple Myeloma

FEATURING Al-Ola Abdallah
  • 414 views
  • August 19, 2019
06:58

KU Hematology & Medical Oncology Review 2019

KU ASCO Review 2019: FDA Approval of Daratumumab in Combination with Len-Dex for Newly Diagnosed, Transplant-Ineligible Patients with Multiple Myeloma

FEATURING Al-Ola Abdallah
  • 159 views
  • August 19, 2019
05:36

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Myeloma Update: Efficacy of KRd With or Without Transplantation in Newly Diagnosed Myeloma According to Risk Status

FEATURING Al-Ola Abdallah
  • 109 views
  • August 19, 2019
06:42

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Myeloma Update: Does Subcutaneous Daratumumab Decrease the Treatment Burden of Daratumumab IV in Myeloma?

FEATURING Al-Ola Abdallah
  • 401 views
  • August 19, 2019
  • 1
04:31

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib & Ibrutinib + Rituximab vs. FCR

FEATURING Marc Hoffmann
  • 386 views
  • October 4, 2019
08:34

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019: Update on CLL Preferred Therapy - Venetoclax + Obinutuzumab

FEATURING Marc Hoffmann
  • 944 views
  • August 19, 2019
  • 4
12:53

KU Hematology & Medical Oncology Review 2019

KU ASCO 2019 Non Hodgkin Lymphoma Update : Polatuzumab Vedotin for R/R DLBCL, Chemo for Waldenstroms, Lenalidomide and Rituximab in Relapsed Indolent Lymphoma, & Induction Rituximab in iNHL

FEATURING Marc Hoffmann
  • 461 views
  • August 19, 2019
  • 3